

FORM 1A

APPLICATION LETTER

**GEMINA LABORATORIES LTD.
3800 Westbrook Mall, Suite 142
Vancouver, BC**

August 3, 2021

Canadian Securities Exchange
100 King Street West, Suite 7210
Toronto, ON M5X 1E1

Dear Sirs/Mesdames:

Re: Qualification for Listing of Gemina Laboratories Ltd. (the "Issuer")

Further to the Issuer's application on April 9, 2021 to have its common shares qualified for listing on the Canadian Securities Exchange (the "Exchange"), we note that there are currently **50,237,959** common shares issued and outstanding, and **13,965,896** common shares reserved for issuance.

Please note that, concurrently with its application on April 9, 2021, the Issuer sent a wire transfer of \$5,000 plus GST, representing the non-refundable portion of the application fee. The Issuer also submitted the following on April 9, 2021: (i) Form 1B Listing Application; (ii) certified copies of the Issuer's charter documents; (iii) Preliminary Prospectus and accompanying financial statements; (iv) draft Escrow Agreement; (v) and duly executed Form 3 PIFs for each Related Party (as defined under CSE policies) of the Issuer.

In addition, we enclose herewith:

- Executed Escrow Agreement;
- Receipt for the Preliminary Prospectus and Final Prospectus from the British Columbia Securities Commission;
- Certificate of good standing of the Issuer;
- Transfer agent confirmation letter;
- Unqualified letter from CDS;
- Confirmation of CUSIP/ISIN eligibility from CDS; and
- Void cheque of the Issuer.

The Issuer also confirms that:

- electronic payment of \$10,500 representing the balance of the application fee (inclusive of GST) has been provided; and

Please note that the following will be submitted under separate cover:

- Final Form 2A Listing Statement (Final Prospectus, table of concordance, section 14 and certificate pages), and blackline to copy previously provided to the CSE on July 7, 2021;
- Form 2B Listing Summary;
- Executed Form 4 Listing Agreement;
- Executed Form 6 Certificate of Compliance;
- Confirmation that a SEDI profile has been created for the Issuer and SEDI insider reports for each person who filed a Form 3 Personal Information Form; and
- Legal opinion to the CSE and officer's certificate in support.

[Remainder of page intentionally left blank]

Yours very truly,

GEMINA LABORATORIES LTD.

Per: "John Davies"

John Davies

Chief Executive Officer and Director